查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
法布裡病治療市場 - 增長,未來前景,競爭分析，2023-2031 年
市場調查報告書
商品編碼
1313690

法布裡病治療市場 - 增長,未來前景,競爭分析，2023-2031 年

Fabry Disease Therapeutic Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031
出版日期: | 出版商: Acute Market Reports | 英文 112 Pages | 商品交期: 最快1-2個工作天內

價格

到 2031 年，法布裡病治療市場預計將增長 6.5% 法布裡病是一種罕見的 X 連鎖遺傳性血脂異常，由 ALPHA-半乳糖甘□ A □活性缺陷引起。 這種□通常負責分解三□基神經□胺，導致某些脂肪物質在全身血管壁上異常沉積。 法布裡病的典型症狀包括疼痛,眼前部渾濁,皮膚上出現暗紅色小斑點,聽力喪失以及危及生命的並發症，如心髒病發作,腎損傷和中風。 法布裡病分為 1 型（具有經典表型）和 2 型（具有遲髮型表型）。 根據NORD（國家罕見疾病組織）的數據，經典1 型表型的發病率約為每40,000 名男性中有1 人，但因人口和種族而異，範圍為大約18,000 到95,000 名男性中的1 人。 男性中 2 型後疾病的發病率因種族,人口統計和種族而異，但在同一地區,種族和種族中至少是經典 1 型表型發病率的 10 倍。

法布裡病無法治愈，但有治療藥物。 採用□替代療法（ERT）進行治療。 目前，市場上只有兩種ERT製劑:Replegal和Fabrazyme，通過靜脈滴注給藥。 在美國，只有Sanofi Genzyme健讚的阿加糖□BETA（Fabrazyme）獲得FDA批准。 Shire 的阿加糖□ alfa (Replagal) 在包括歐洲在內的許多國家獲得批准，但在美國尚未獲得批准。 Fabrazyme 和 Repregal 終生每兩週給藥一次，或者直到有另一種合適的藥物可用為止。 ERT 是一種非常昂貴的治療方法。 其他治療可能包括緩解症狀的藥物，例如止痛藥,治療胃部不適的藥物,血液稀釋劑以及治療心律失常和其他心臟問題的藥物。

全球法布裡病治療市場的主要驅動因素包括在研發方面廣泛探索和採用先進技術。 多種治療藥物正在進行臨床試驗，包括 SMP-536,PRX-102,AT-1001,GC-1119,SAR-402671 和 PRX-102。 法布裡病已被政府和私人保險公司指定為 ICD-10-CM 代碼，可用於指示診斷以用於報銷。 全球法布裡病市場增長的主要障礙是該病的罕見發病率（四萬分之一）。

Genzyme-Sanofi 和 Shire 等公司是市場上的主要參與者。 參與新藥開發的主要公司包括Amicus Therapeutics, Shire, Genzyme Sanofi, Protalix, Sanofi-Aventis LLC, Novartis Pharmaceuticals, Pfizer, Bristol-Myers Squibb, GlaxoSmithKline, Amgen, Teva Pharmaceutical Industries, Merck And Company, AbbVie, Takeda Pharmaceutical, Green Cross, Takeda Pharmaceutical等主要公司。

此報告提供:

  • 法布裡病治療全球市場概覽
  • 2014年至2024年的市場趨勢評估（包含2014年和2015年的歷史信息,截至2024年的預測以及2016年至2024年的每年復合年增長率）
  • 定性評估工具，例如市場驅動因素,挑戰,未來前景等。
  • 市場份額分析和分形圖評估等市場競爭審查工具
  • 根據當前和預計的市場動態，重點關注各個級別的產品批准,發布和市場細分
  • 行業結構概覽
  • 公司簡介，重點介紹法布裡病治療市場主要運營公司的關鍵信息

目錄

第一章前言

  • 報告內容
    • 報告的目的
    • 目標受眾
    • 提供的主要產品
  • 市場細分
  • 調查方法
    • 第一階段-二次調查
    • 第二階段 - 初步調查
    • 第三階段-專家評審
    • 先決條件
    • 採用的方法

第 2 章執行摘要

第三章法布裡病治療市場:競爭分析

  • 主要供應商的市場地位
  • 供應商採取的策略
  • 主要產業戰略
  • 層級分析:2022 年與 2031 年

第四章法布裡病治療市場:宏觀分析和市場動態

  • 簡介
  • 2021-2031 年全球法布裡病治療市場價值
  • 市場動態
    • 市場驅動因素
    • 市場製約因素
    • 主要挑戰
    • 主要機會
  • 促進因素和抑制因素的影響分析
  • 蹺蹺板分析

第 5 章法布裡病治療市場:按藥物類型 2021-2031

  • 市場概覽
  • 增長/利潤分析:2022 年與 2031 年
  • 市場細分
    • □替代療法
    • 替代療法

第六章2021-2031年北美法布裡病治療市場

  • 市場概覽
  • 法布裡病治療市場:按藥物類型 2021-2031
  • 法布裡病治療市場:按地區劃分 2021-2031
    • 北美
      • 美國
      • 加拿大
      • 其他北美地區

第 7 章英國和歐盟法布裡病治療市場 2021-2031

  • 市場概覽
  • 法布裡病治療市場:按藥物類型 2021-2031
  • 法布裡病治療市場:按地區劃分 2021-2031
    • 英國和歐盟
      • 英國
      • 德國
      • 西班牙
      • 意大利
      • 法國
      • 其他歐洲地區

第8章2021-2031年亞太法布裡病治療市場

  • 市場概覽
  • 法布裡病治療市場:按藥物類型 2021-2031
  • 法布裡病治療市場:按地區劃分 2021-2031
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區

第 9 章 2021-2031 年拉丁美洲法布裡病治療市場

  • 市場概覽
  • 法布裡病治療市場:按藥物類型分類 2021-2031
  • 法布裡病治療市場:按地區劃分 2021-2031
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 其他拉丁美洲地區

第10章2021-2031年中東和非洲法布裡病治療市場

  • 市場概覽
  • 法布裡病治療市場:按藥物類型分類 2021-2031
  • 法布裡病治療市場:按地區劃分 2021-2031
    • 中東/非洲
      • 海灣合作委員會
      • 非洲
      • 其他中東/非洲地區

第十一章公司簡介

  • Amicus therapeutics
  • Shire
  • Genzyme-Sanofi
  • Protalix
  • Sanofi-Aventis LLC
  • Novartis Pharmaceuticals
  • Pfizer
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc
  • Amgen Inc.
  • Teva pharmaceutical Industries Ltd.
  • Merck & Co.
  • AbbVie Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Green Cross Corp.
  • 其他主要公司
Product Code: 137335-06-23

Fabry disease therapeutic market expected to Grow at 6.5% by 2031, Fabry disease is a rare, X-linked inherited, disorder of lipid metabolism resulting from the deficient activity of the enzyme, alpha-galactosidase-A. This enzyme normally responsible for the breakdown of globotriaosylceramide, results in abnormal deposits of a particular fatty substance in walls of the blood vessel throughout the body. Characteristic features of Fabry disease include episodes of pain, cloudiness of the front part of the eye, clusters of small and dark red spots on the skin, hearing loss also involves life-threatening complications such as heart attack, kidney damage and stroke. Fabry disease can be divided into two types, type 1 classic phenotype and type 2 later-onset phenotype. According to National Organization for Rare Disorder (NORD) the incidence of type 1 classic phenotype is about 1 in 40,000 in males, but varies with demography and race, ranging from about 1 in 18,000 to 1 in 95,000. The incidence of type 2 later-onset in males varies by ethnicity, demography and race, but is at least 10 times more frequent than that of the type 1 classic phenotype from the same region, ethnic group or race.

There is no cure for Fabry disease, but medications are available treat the condition. Enzyme Replacement Therapy (ERT) is used for treatment. Currently only two ERT preparations such as Replagal and Fabrazyme are available in the market that are administered by intravenous infusion. In the USA, only Sanofi-Genzyme's agalsidase beta (Fabrazyme) is FDA approved. Shire's Agalsidase alfa (Replagal) is approved in Europe and many other countries but not in the United States. Fabrazyme and Replagal is administered after every two weeks for lifetime or until another appropriate medication becomes available. ERT is extremely expensive treatment. Other treatment may also involve medications to reduce symptoms such as pain medications, medications to treat stomach hyperactivity, blood thinners and medication to manage arrhythmias and other heart disorders.

Key drivers for the global fabry disease therapeutic market includes, extensive investigations and adoption of advance technology in research and development. Various therapeutic products, such as, SMP-536, PRX-102, AT-1001, GC-1119, SAR-402671, PRX-102 and other are in clinical trial studies. Fabry disease has been designated ICD-10-CM code by government and private insurance that can be used to indicate diagnosis for reimbursement purpose, which would further drive the market. Major barriers of growth for the global for Fabry disease market is rare incidence rate of the disorder (1:40,000).

Companies such as Genzyme-Sanofi and Shire are the major player in market as only these company have approved drugs in the market currently. Major players involved in development of new medications include Amicus therapeutics, Shire, Genzyme-Sanofi, Protalix, Sanofi-Aventis LLC, Novartis Pharmaceuticals, Pfizer, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Amgen Inc., Teva pharmaceutical Industries Ltd., Merck & Co., AbbVie Inc., Takeda Pharmaceutical Co. Ltd., Green Cross Corp. And Other Notable Players.

This report offers:

  • An overview of the global markets for Fabry Disease Therapeutics
  • Market trends assessment for the period 2014-2024, with historical information for 2014 & 2015, and projections through 2024, with respective CAGRS during 2016-2024
  • Qualitative assessment tools such as market drivers, challenges and future prospects.
  • Market competition scrutiny tools such as market share analysis, fractal map assessment.
  • Focus on each level of market segmentation based on product approvals, launch, and current and anticipated market dynamics.
  • A general overview of the industry structure
  • Company profiles highlighting key information about the major players operating in the Fabry Disease Therapeutics Market

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofFabry Disease Therapeutic market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Fabry Disease Therapeutic market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Type

  • Enzyme Replacement Therapy
  • Alternative therapies

Region Segment (2021-2031; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Fabry Disease Therapeutic market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Fabry Disease Therapeutic market?
  • Which is the largest regional market for Fabry Disease Therapeutic market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Fabry Disease Therapeutic market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Fabry Disease Therapeutic market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Fabry Disease Therapeutic Market
  • 2.2. Global Fabry Disease Therapeutic Market, By Drug Type, 2022 (US$ Million)
  • 2.3. Global Fabry Disease Therapeutic Market, By Geography, 2022 (US$ Million)
  • 2.4. Attractive Investment Proposition by Geography, 2022

3. Fabry Disease Therapeutic Market: Competitive Analysis

  • 3.1. Market Positioning of Key Fabry Disease Therapeutic Market Vendors
  • 3.2. Strategies Adopted by Fabry Disease Therapeutic Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. Fabry Disease Therapeutic Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Fabry Disease Therapeutic Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. Enzyme Replacement Therapy
    • 5.3.2. Alternative therapies

6. North America Fabry Disease Therapeutic Market, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
  • 6.3.Fabry Disease Therapeutic Market: By Region, 2021-2031, USD (Million)
    • 6.3.1.North America
      • 6.3.1.1. U.S.
        • 6.3.1.1.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 6.3.1.2. Canada
        • 6.3.1.2.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 6.3.1.3. Rest of North America
        • 6.3.1.3.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)

7. UK and European Union Fabry Disease Therapeutic Market, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
  • 7.3.Fabry Disease Therapeutic Market: By Region, 2021-2031, USD (Million)
    • 7.3.1.UK and European Union
      • 7.3.1.1. UK
        • 7.3.1.1.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 7.3.1.2. Germany
        • 7.3.1.2.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 7.3.1.3. Spain
        • 7.3.1.3.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 7.3.1.4. Italy
        • 7.3.1.4.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 7.3.1.5. France
        • 7.3.1.5.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 7.3.1.6. Rest of Europe
        • 7.3.1.6.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)

8. Asia Pacific Fabry Disease Therapeutic Market, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
  • 8.3.Fabry Disease Therapeutic Market: By Region, 2021-2031, USD (Million)
    • 8.3.1.Asia Pacific
      • 8.3.1.1. China
        • 8.3.1.1.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 8.3.1.2. Japan
        • 8.3.1.2.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 8.3.1.3. India
        • 8.3.1.3.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 8.3.1.4. Australia
        • 8.3.1.4.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 8.3.1.5. South Korea
        • 8.3.1.5.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 8.3.1.6. Rest of Asia Pacific
        • 8.3.1.6.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)

9. Latin America Fabry Disease Therapeutic Market, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
  • 9.3.Fabry Disease Therapeutic Market: By Region, 2021-2031, USD (Million)
    • 9.3.1.Latin America
      • 9.3.1.1. Brazil
        • 9.3.1.1.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 9.3.1.2. Mexico
        • 9.3.1.2.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 9.3.1.3. Rest of Latin America
        • 9.3.1.3.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)

10. Middle East and Africa Fabry Disease Therapeutic Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
  • 10.3.Fabry Disease Therapeutic Market: By Region, 2021-2031, USD (Million)
    • 10.3.1.Middle East and Africa
      • 10.3.1.1. GCC
        • 10.3.1.1.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 10.3.1.2. Africa
        • 10.3.1.2.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 10.3.1.3. Rest of Middle East and Africa
        • 10.3.1.3.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)

11. Company Profile

  • 11.1. Amicus therapeutics
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Portfolio
    • 11.1.4. Strategic Initiatives
  • 11.2. Shire
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Portfolio
    • 11.2.4. Strategic Initiatives
  • 11.3. Genzyme-Sanofi
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Portfolio
    • 11.3.4. Strategic Initiatives
  • 11.4. Protalix
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Portfolio
    • 11.4.4. Strategic Initiatives
  • 11.5. Sanofi-Aventis LLC
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Portfolio
    • 11.5.4. Strategic Initiatives
  • 11.6. Novartis Pharmaceuticals
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Portfolio
    • 11.6.4. Strategic Initiatives
  • 11.7. Pfizer
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Portfolio
    • 11.7.4. Strategic Initiatives
  • 11.8. Bristol-Myers Squibb Company
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Portfolio
    • 11.8.4. Strategic Initiatives
  • 11.9. GlaxoSmithKline plc
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Portfolio
    • 11.9.4. Strategic Initiatives
  • 11.10. Amgen Inc.
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Portfolio
    • 11.10.4. Strategic Initiatives
  • 11.11. Teva pharmaceutical Industries Ltd.
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Portfolio
    • 11.11.4. Strategic Initiatives
  • 11.12. Merck & Co.
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Portfolio
    • 11.12.4. Strategic Initiatives
  • 11.13. AbbVie Inc.
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Product Portfolio
    • 11.13.4. Strategic Initiatives
  • 11.14. Takeda Pharmaceutical Co. Ltd.
    • 11.14.1. Company Overview
    • 11.14.2. Financial Performance
    • 11.14.3. Product Portfolio
    • 11.14.4. Strategic Initiatives
  • 11.15. Green Cross Corp.
    • 11.15.1. Company Overview
    • 11.15.2. Financial Performance
    • 11.15.3. Product Portfolio
    • 11.15.4. Strategic Initiatives
  • 11.16. Other Notable Players
    • 11.16.1. Company Overview
    • 11.16.2. Financial Performance
    • 11.16.3. Product Portfolio
    • 11.16.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 2 North America Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 3 U.S. Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 4 Canada Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 5 Rest of North America Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 6 UK and European Union Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 7 UK Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 8 Germany Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 9 Spain Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 10 Italy Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 11 France Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 12 Rest of Europe Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 13 Asia Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 14 China Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 15 Japan Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 16 India Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 17 Australia Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 18 South Korea Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 19 Latin America Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 20 Brazil Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 21 Mexico Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 22 Rest of Latin America Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 23 Middle East and Africa Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 24 GCC Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 25 Africa Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 26 Rest of Middle East and Africa Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)

List of Figures

  • FIG. 1 Global Fabry Disease Therapeutic Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Fabry Disease Therapeutic Market: Quality Assurance
  • FIG. 5 Global Fabry Disease Therapeutic Market, By Drug Type, 2022
  • FIG. 6 Global Fabry Disease Therapeutic Market, By Geography, 2022
  • FIG. 7 Market Geographical Opportunity Matrix - Global Fabry Disease Therapeutic Market, 2022

FIG. 8Market Positioning of Key Fabry Disease Therapeutic Market Players, 2022

FIG. 9Global Fabry Disease Therapeutic Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031

  • FIG. 10 Global Fabry Disease Therapeutic Market, By Drug Type, 2022 Vs 2031, %
  • FIG. 11 U.S. Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 12 Canada Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 13 Rest of North America Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 14 UK Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 15 Germany Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 16 Spain Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 17 Italy Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 18 France Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 19 Rest of Europe Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 20 China Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 21 Japan Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 22 India Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 23 Australia Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 24 South Korea Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 25 Rest of Asia Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 26 Brazil Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 27 Mexico Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 28 Rest of Latin America Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 29 GCC Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 30 Africa Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 31 Rest of Middle East and Africa Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031